Focus: ORIC Pharmaceuticals is an early-stage oncology-focused biotech company based in South San Francisco specializing in cancer drug resistance and solid tumors. The company is pre-revenue with a clinical-stage pipeline concentrated in Phase 1 programs.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Stable — net +3 jobs in 30d
5 added, 2 removed. Backfill posture.
ORIC is a scientifically focused pre-revenue biotech bet for early-career or clinical specialists willing to accept execution risk for equity upside and technical depth.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for ORIC Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from ORIC Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles